Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic has received approval from the FDA for the Endeavor Zotarolimus-Eluting Coronary Stent System to be used in the treatment of coronary artery disease.
Subscribe to our email newsletter
The approval gives US cardiologists access to a new medical device for safely and effectively treating patients with narrowed coronary arteries. Clinical research has shown that Endeavor provides a consistent and sustained reduction in the need for repeat procedures compared to a bare-metal stent, while also maintaining an excellent safety profile. The Endeavor stent is said to be the first new drug-eluting stent approved by the FDA since 2004. The US market launch of the Endeavor stent will begin immediately.
Scott Ward, president of the CardioVascular business at Medtronic, said: “We expect to ship 100,000 units to US hospitals in the next 30 days to assure full availability of this next-generation technology.”